Anatara Lifesciences (ASX: ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need.
Anatara is a specialist life sciences company with expertise in developing products for human and animal health. We are currently focused on building a pipeline of evidence-based gastrointestinal health products, through in-house development and in-licencing.
Human Applications
Our initial Gastrointestinal ReProgramming (GaRP) over-the-counter medicine is focused on addressing the chronic symptoms associated with irritable bowel syndrome (IBS) and the inflammatory bowel diseases (IBD). 11% of the global population is affected by IBS and there are 5 million IBD sufferers worldwide. GaRP has been designed as an everyday option for patients to manage ongoing chronic symptoms as well as minimise episodic flare ups.
A new formulation 3FDC was developed using GaRP technology. 3FDC is released in the large intestine (colon) to positively influence the gut-brain connection, targeting modulation of psychobiological processes driving anxiety-related disorders and to assist homeostasis of the gut to promote overall health and wellbeing.
Anatara is seeking global commercialisation partners for GaRP and 3FDC.
Animal Applications
Detach®, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour in livestock) in piglets. Scour in piglets is an expensive, debilitating and in some cases, life-threatening condition. Detach® is safe and effective. New formulations, BONIFF (in-feed formulation for piglets) and ANR-pf (poultry formulation), successfully completed challenge studies.
Anatara is seeking commercialisation partners for Detach®, BONIFF and ANR-pf.
About Us
Backed by a well credentialed Board and Management team, and world-leading scientific collaborators, Anatara is uniquely positioned to fulfill a significant unmet medical need in gut health.
